PUBLICATION : Efficacy of rituximab in refractory RRMS
OBJECTIVE: To investigate the efficacy of rituximab as rescue therapy in patients with relapsing-remitting multiple sclerosis (RRMS) and persistent disease activity confirmed by magnetic resonance imaging (MRI) despite immunosuppressive disease-modifying therapy (DMT).
CONCLUSION: This study provides level IV evidence that rituximab reduces clinical and MRI disease activity in patients with active RRMS despite immunosuppressive DMT.
Auteurs
Pierre Durozard, Adil Maarouf, Clémence Boutiere, Aurelie Ruet, Bruno Brochet, Sandra Vukusic, Clarisse Carra-Dalliere, Pierre Labauge, Guillaume Mathey, Marc Debouverie, Caroline Papeix, Elisabeth Maillart, Catherine Lubetzki, Caroline Bensa, Olivier Gout, Claire Giannesini, Bruno Stankoff, Jonathan Ciron, David Brassat, Jean Pelletier, Audrey Rico Lamy, Bertrand Audoin on behalf of the SFSEP and OFSEP groups